{"nctId":"NCT02738333","briefTitle":"Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection","startDateStruct":{"date":"2016-04-12","type":"ACTUAL"},"conditions":["Hepatitis C Virus Infection"],"count":239,"armGroups":[{"label":"LDV/SOF (Cohort 1)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"SOF+RBV (Cohort 1)","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]},{"label":"LDV/SOF (Cohort 2)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]}],"interventions":[{"name":"LDV/SOF","otherNames":["Harvoni®","GS-5885/GS-7977"]},{"name":"SOF","otherNames":["Sovaldi®","GS-7977","PSI-7977"]},{"name":"RBV","otherNames":["REBETOL®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Chronic genotype 2 HCV-infected males and non-pregnant/non-lactating females\n* Aged 20 years or older\n* Treatment naive or treatment experienced\n* At least 20 subjects will have Child-Pugh-A compensated cirrhosis. In Cohort 2, participants must be ineligible or intolerant of RBV.\n\nKey Exclusion Criteria:\n\n* Previous exposure to an NS5A or NS5B inhibitor\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n* Pregnant or nursing female or male with pregnant female partner\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null},{"groupId":"OG001","value":"95.4","spread":null},{"groupId":"OG002","value":"96.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)","description":"SVR4 was defined as HCV RNA \\< LLOQ at 4 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":null},{"groupId":"OG001","value":"98.1","spread":null},{"groupId":"OG002","value":"96.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)","description":"SVR 24 was defined as HCV RNA \\< LLOQ at 24 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null},{"groupId":"OG001","value":"95.4","spread":null},{"groupId":"OG002","value":"96.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null},{"groupId":"OG001","value":"31.5","spread":null},{"groupId":"OG002","value":"32.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 2","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.6","spread":null},{"groupId":"OG001","value":"76.6","spread":null},{"groupId":"OG002","value":"76.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 3","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.6","spread":null},{"groupId":"OG001","value":"90.7","spread":null},{"groupId":"OG002","value":"96.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 4","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"96.3","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 5","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"99.1","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"99.1","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 10","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.18","spread":"0.540"},{"groupId":"OG001","value":"-4.34","spread":"0.602"},{"groupId":"OG002","value":"-4.24","spread":"0.550"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 2","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.76","spread":"0.759"},{"groupId":"OG001","value":"-4.81","spread":"0.772"},{"groupId":"OG002","value":"-4.64","spread":"0.719"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 3","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.87","spread":"0.780"},{"groupId":"OG001","value":"-4.89","spread":"0.790"},{"groupId":"OG002","value":"-4.75","spread":"0.714"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 4","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.89","spread":"0.782"},{"groupId":"OG001","value":"-4.91","spread":"0.794"},{"groupId":"OG002","value":"-4.76","spread":"0.719"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 5","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.91","spread":"0.781"},{"groupId":"OG001","value":"-4.92","spread":"0.794"},{"groupId":"OG002","value":"-4.76","spread":"0.719"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.91","spread":"0.781"},{"groupId":"OG001","value":"-4.92","spread":"0.793"},{"groupId":"OG002","value":"-4.76","spread":"0.719"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.92","spread":"0.785"},{"groupId":"OG001","value":"-4.93","spread":"0.794"},{"groupId":"OG002","value":"-4.76","spread":"0.719"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 10","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.92","spread":"0.785"},{"groupId":"OG001","value":"-4.93","spread":"0.794"},{"groupId":"OG002","value":"-4.76","spread":"0.719"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.92","spread":"0.785"},{"groupId":"OG001","value":"-4.92","spread":"0.794"},{"groupId":"OG002","value":"-4.76","spread":"0.719"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Overall Virologic Failure","description":"Virologic failure was defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"3.7","spread":null},{"groupId":"OG002","value":"4.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":106},"commonTop":["Viral upper respiratory tract infection","Anaemia","Headache","Stomatitis","Pyrexia"]}}}